FDA clears Zyrtec line extension
This article was originally published in The Tan Sheet
Executive Summary
McNeil Consumer Healthcare gains regulatory approval for Zyrtec Allergy orally disintegrating tablets (cetirizine 10 mg). In a Sept. 3 1letter, FDA's Division of Nonprescription Clinical Evaluation green-lights McNeil's new drug application, submitted in November 2009, for 6-, 12-, 24- and 66-count cartons of the OTC. The Johnson & Johnson subsidiary has fulfilled the pediatric study requirements for the Zyrtec extension, FDA adds. J&J/McNeil declined to comment on when the tablets will launch. With generics readily available, Zyrtec and other brands seek innovative delivery formats to stay a step ahead of private label (2"The Tan Sheet" Oct. 6, 2008)
You may also be interested in...
Fending Off Private Label Competition: Innovation Is Key
Innovative drug delivery, claims and packaging are keys to defending name brands from private label competition as consumers grow increasingly price sensitive
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.